Misplaced Pages

Medical uses of silver: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 09:40, 24 November 2008 editArthur Rubin (talk | contribs)Extended confirmed users, Rollbackers130,168 edits remove irrelevant; colloidal silver is not ionic. Undid revision 253689739 by DHawker (talk)← Previous edit Revision as of 10:06, 24 November 2008 edit undoDHawker (talk | contribs)183 edits Undid revision 253761731 by ]\ The 'broader definition' as defined in the opening para includes ionic products.Next edit →
Line 2: Line 2:


'''Colloidal silver''' is a ] ] of ] particles of ]. A ] is technically defined as particles which remain suspended without forming an ], or dissolved solution. The broader commercial definition of "colloidal silver" includes products that contain various concentrations of ionic silver, silver colloids, ionic silver compounds or silver proteins in purified ]. Colloidal silver with concentrations of 30 ] (ppm) or less are typically manufactured using an ] process, whereas colloidal silver with higher concentrations of 50 ppm or more are usually either silver compounds such as silver chloride and silver iodide or are solutions that have been bound with a protein to disperse the particles. '''Colloidal silver''' is a ] ] of ] particles of ]. A ] is technically defined as particles which remain suspended without forming an ], or dissolved solution. The broader commercial definition of "colloidal silver" includes products that contain various concentrations of ionic silver, silver colloids, ionic silver compounds or silver proteins in purified ]. Colloidal silver with concentrations of 30 ] (ppm) or less are typically manufactured using an ] process, whereas colloidal silver with higher concentrations of 50 ppm or more are usually either silver compounds such as silver chloride and silver iodide or are solutions that have been bound with a protein to disperse the particles.

Laboratory tests show silver ions and silver compounds have a toxic effect on some bacteria, viruses, algae and fungi. Its germicidal effects kill many microbial organisms '']'', but human testing and standardization of silver products is difficult.<ref>{{cite journal |author=Chopra I |title=The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern? |journal=The Journal of antimicrobial chemotherapy |volume=59 |issue=4 |pages=587–90 |year=2007 |month=April |pmid=17307768 |doi=10.1093/jac/dkm006}}</ref>


Currently, colloidal silver is marketed as an ], though there is no scientific evidence of its effectiveness for any medical condition.<ref name="md-anderson"/><ref name="nccam"/> Excessive use can result in ], a form of silver toxicity. Currently, colloidal silver is marketed as an ], though there is no scientific evidence of its effectiveness for any medical condition.<ref name="md-anderson"/><ref name="nccam"/> Excessive use can result in ], a form of silver toxicity.

Revision as of 10:06, 24 November 2008

Part of a series of articles on
Nanomaterials
Carbon nanotubes
Fullerenes
Other nanoparticles
Nanostructured materials

Colloidal silver is a liquid suspension of microscopic particles of silver. A colloid is technically defined as particles which remain suspended without forming an ionic, or dissolved solution. The broader commercial definition of "colloidal silver" includes products that contain various concentrations of ionic silver, silver colloids, ionic silver compounds or silver proteins in purified water. Colloidal silver with concentrations of 30 parts per million (ppm) or less are typically manufactured using an electrolysis process, whereas colloidal silver with higher concentrations of 50 ppm or more are usually either silver compounds such as silver chloride and silver iodide or are solutions that have been bound with a protein to disperse the particles.

Laboratory tests show silver ions and silver compounds have a toxic effect on some bacteria, viruses, algae and fungi. Its germicidal effects kill many microbial organisms in vitro, but human testing and standardization of silver products is difficult.

Currently, colloidal silver is marketed as an alternative medical remedy, though there is no scientific evidence of its effectiveness for any medical condition. Excessive use can result in argyria, a form of silver toxicity.

History and Applications

Prior to 1938, colloidal silver was widely promoted as a "cure-all", and silver products were prescribed by physicians as topical antibiotics. However, with the development of more effective, less expensive antibiotics such as penicillin and sulfanilamide, medical use of colloidal silver ceased. From approximately 1990, there has been a resurgence of the promotion of colloidal silver as an alternative medicine treatment, marketed with claims that it can prevent or treat numerous diseases.

Colloidal silver products are legally available at health food stores in the United States and Australia and are marketed over the Internet as a dietary supplement. It is illegal in the U.S. and Australia for marketers to make claims of medical effectiveness for colloidal silver, but some websites still list its use for the prevention of colds and flu, and the treatment of more serious conditions such as diabetes, cancer, chronic fatigue syndrome, HIV/AIDS, and tuberculosis, among other diseases. Colloidal silver has been found to lack any antimicrobial effect, and there is no medical evidence that colloidal silver is effective for any of these claimed indications. Silver is not an essential mineral in humans; there is no dietary requirement for silver, and no such thing as a silver "deficiency".

Currently, there are no evidence-based medical uses for colloidal silver. There are no clinical studies in humans demonstrating effectivness, and several reports of toxicity. The U.S. National Center for Complementary and Alternative Medicine has issued an advisory indicating that the marketing claims made about colloidal silver are scientifically unsupported, and that the silver content of marketed supplements varies widely and can pose risks to the consumer.

Toxicities and interactions

Main article: Argyria

Excessive intake of silver products may result in a condition known as argyria, one symptom of which is blue or gray discoloration of the skin. The discoloration occurs when silver is deposited in the skin and then darkened by sunlight, just as silver particles in photographic film darken when exposed to sunlight. Localized argyria can occur as a result of topical use of silver-containing remedies, while generalized argyria results from the ingestion of colloidal silver. Arygria is usually permanent, and there is no known effective treatment. While argyria is usually benign and limited to skin discoloration, there are isolated reports of more serious neurologic, renal, or hepatic complications. A death has been reported in the medical literature as a result of colloidal silver use; in that case, a 71-year-old man developed status epilepticus which the authors felt was due to silver toxicity.

A number of case reports describe argyria after ingestion of colloidal silver marketed as an alternative-medicine treatment. Colloidal silver may theoretically interact with some medications, including tetracycline and quinolone antibiotics and penicillamine, reducing the effectiveness of those medications.

Government regulation

In August 1999, the U.S. Food and Drug Administration (FDA) banned colloidal silver sellers from claiming any therapeutic value for the product, noting that such products were being marketed for numerous diseases without evidence of effectiveness. The FDA also banned over-the-counter sale of drug products containing colloidal silver due to the lack of safety or efficacy data. The product now has the status of a dietary supplement in the US; it can be promoted with general "structure-function" claims, but cannot be marketed as preventing or treating any illness.

Following this ruling, the FDA has issued numerous warnings to Internet sites which have continued to promote colloidal silver as an antibiotic or for other medical purposes.

In 2002, the Australian Therapeutic Goods Administration (TGA) ruled that colloidal silver-containing products were no longer exempt from therapeutic goods legislation and had to meet the requirements of other products covered by this law. The TGA found that "there are no current legitimate uses of colloidal silver and that the Surveillance Section of the TGA be requested to investigate the illegal availability of colloidal silver products because of concerns about their significant toxicity. The reasons for the recommendation were that:

There is little evidence to support therapeutic claims made for colloidal silver products; the risk to consumers of silver toxicity outweighs the value of trying an unsubstantiated treatment, and bacterial resistance to silver can occur; and efforts should be made to curb the illegal availability of colloidal silver products, which is a significant public health issue.

See also

References

  1. Chopra I (2007). "The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern?". The Journal of antimicrobial chemotherapy. 59 (4): 587–90. doi:10.1093/jac/dkm006. PMID 17307768. {{cite journal}}: Unknown parameter |month= ignored (help)
  2. ^ "Complementary/Integrative Medicine Therapies: Colloidal Silver". M. D. Anderson Cancer Center. February 2008. Retrieved 2008-10-03.
  3. ^ "Colloidal Silver Products". National Center for Complementary and Alternative Medicine. December 2006. Retrieved 2008-10-06.
  4. ^ Newman M, Kolecki P (2001). "Argyria in the ED". Am J Emerg Med. 19 (6): 525–6. doi:10.1053/ajem.2001.25773. PMID 11593479. {{cite journal}}: Unknown parameter |month= ignored (help)
  5. Fung MC, Bowen DL (1996). "Silver products for medical indications: risk-benefit assessment". J. Toxicol. Clin. Toxicol. 34 (1): 119–26. PMID 8632503.
  6. Fung MC, Weintraub M, Bowen DL (1995). "Colloidal silver proteins marketed as health supplements". JAMA. 274 (15): 1196–7. PMID 7563503. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  7. Wadhera A, Fung M (2005). "Systemic argyria associated with ingestion of colloidal silver". Dermatol. Online J. 11 (1): 12. PMID 15748553.
  8. van Hasselt P, Gashe BA, Ahmad J (2004). "Colloidal silver as an antimicrobial agent: fact or fiction?". J Wound Care. 13 (4): 154–5. PMID 15114827. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  9. ^ "Over-the-counter drug products containing colloidal silver ingredients or silver salts. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Final rule". Fed Regist. 64 (158): 44653–8. 1999. PMID 10558603. {{cite journal}}: Unknown parameter |month= ignored (help)
  10. ^ "About Herbs: Colloidal Silver". Memorial Sloan-Kettering Cancer Center. 2008-07-25. Retrieved 2008-10-03.
  11. Baker CD, Federico MJ, Accurso FJ (2007). "Case report: skin discoloration following administration of colloidal silver in cystic fibrosis". Curr. Opin. Pediatr. 19 (6): 733–5. doi:10.1097/MOP.0b013e3282f11fee. PMID 18025945. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  12. ^ Brandt D, Park B, Hoang M, Jacobe HT (2005). "Argyria secondary to ingestion of homemade silver solution". J. Am. Acad. Dermatol. 53 (2 Suppl 1): S105–7. doi:10.1016/j.jaad.2004.09.026. PMID 16021155. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  13. Mirsattari SM, Hammond RR, Sharpe MD, Leung FY, Young GB (2004). "Myoclonic status epilepticus following repeated oral ingestion of colloidal silver". Neurology. 62 (8): 1408–10. PMID 15111684. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  14. Case reports of argyria related to colloidal silver products include:
  15. "Colloidal Silver Not Approved". U.S. Food and Drug Administration. 2007-02-12. Retrieved 2008-09-22.
  16. "FDA Warning Letter" (PDF). U.S. Food and Drug Administration. 2001-03-13. Retrieved 2008-09-22.
  17. "Regulation of colloidal silver and related products". Australian Therapeutic Goods Administration. 2005-11-09. Retrieved 2008-09-22.

External links

Categories: